GlassScriptPhysician profile
Syed A Hussain
NPI 1689847709
$6,160.51
in general payments reported to CMS, 2019-2025
38 companies · $627 in 2025
The $627 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $865 · 2020: $463 · 2021: $848 · 2022: $673 · 2023: $982 · 2024: $1,703 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,803 · Travel and Lodging: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,803.25 |
| Travel and Lodging | $508.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,012.36 | 2019-2025 | Watchman Access System, Avvigo Guidance System, Watchman Flx |
| Medtronic, INC. | $808.01 | 2021-2025 | Corevalve Evolut R, Symplicity G3 |
| Novartis Pharmaceuticals Corporation | $494.72 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $486.85 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $432.21 | 2019-2024 | Farxiga, Wainua |
| Abiomed | $391.33 | 2019-2024 | Impella |
| Amgen INC. | $376.36 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $361.63 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $230.02 | 2024-2025 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $184.21 | 2019-2023 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $120.24 | 2021-2025 | Nexletol |
| Abbott Laboratories | $119.82 | 2023-2025 | Mitraclip, Triclip |
| Cook Medical LLC | $118.53 | 2019 | |
| Kestra Medical Technology Services, INC. | $112.75 | 2025 | Assure Wcd |
| Novo Nordisk INC | $100.72 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Hussain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.